Barrons
01 Sept 2026, 17:23 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen · Founder & analyst
What the story claims
2 claims · each scored for market impact
Alumis's drug envudeucitinib failed to meet the primary endpoint of a mid-stage trial. — Failure to meet primary endpoints in mid-stage trials typically suggests a lower probability of FDA approval and reduces the drug's expected future cash flows.
-0.90Alumis shares declined following the announcement of the trial results. — Direct market confirmation of negative sentiment and loss of valuation based on the clinical failure.
-0.30Which stocks this story touches
Shares sank after a mid-stage trial failed to meet its primary endpoint.
Continue reading
6 related stories
Search tags
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
PRNewsWire
18h ago
